Literature DB >> 27062604

Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder.

Jon F Pennycuff1, Stacey C Schutte1, Catherine O Hudson1, Deborah R Karp1, Anna P Malykhina2, Gina M Northington1.   

Abstract

AIMS: The aim of this study was to compare the expression of urinary nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), substance P (SP), and calcitonin-gene related peptide (CGRP) in women with and without overactive bladder (OAB). We sought to determine factors associated with higher expression of these neuropeptides.
METHODS: Participants with OAB and age-matched controls were enrolled. Symptom severity was assessed with validated questionnaires. Urinary neurotrophin levels, symptom scores, and clinical data were compared between the groups. Multivariate analysis determined independent factors associated with urinary neurotrophin levels.
RESULTS: Sixty-seven women (38 OAB, 29 controls) were included. Women with OAB and controls were similar in age, race, body mass index, parity, and smoking status. Women with OAB were more likely to report a history of pelvic pain and pelvic surgery. Neurotrophic factor levels normalized to urinary creatinine did not differ between the groups. Increasing age was associated with greater urinary levels of BDNF and NGF (β = 0.23, 95%CI 0.11-0.34 and 0.75, 95%CI 0.17-1.33, respectively, P < 0.02). Higher urinary NGF was associated with increasing BMI (β = 0.81, 95%CI 0.05-1.57, P = 0.04) while pain was associated with elevated urinary SP (β = 0.21, 95%CI 0.09-0.33, P = 0.001).
CONCLUSIONS: Our data does not support a relationship between urinary neurotrophin levels and OAB in age-matched postmenopausal women. Further research is necessary to elucidate the role of urinary neurotrophins in the diagnosis and management of OAB. Neurourol. Urodynam. 36:740-744, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  nerve growth factors; neuropeptides; overactive; substance P; urinary bladder

Mesh:

Substances:

Year:  2016        PMID: 27062604     DOI: 10.1002/nau.23011

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  6 in total

1.  Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.

Authors:  Holly E Richter; Pamela Moalli; Cindy L Amundsen; Anna P Malykhina; Dennis Wallace; Rebecca Rogers; Deborah Myers; Maria Paraiso; Michael Albo; Haolin Shi; Tracy Nolen; Susie Meikle; R Ann Word
Journal:  J Urol       Date:  2017-01-13       Impact factor: 7.450

2.  Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses.

Authors:  Nazema Y Siddiqui; Brian T Helfand; Victor P Andreev; Joseph T Kowalski; Megan S Bradley; H Henry Lai; Mitchell B Berger; Margaret G Mueller; Jennifer A Bickhaus; Vignesh T Packiam; Dee Fenner; Brenda W Gillispie; Ziya Kirkali
Journal:  J Urol       Date:  2019-10-09       Impact factor: 7.450

3.  Urine Nerve Growth Factor May Not Be Useful as a Biomarker of Overactive Bladder in Patients with Pelvic Organ Prolapse.

Authors:  Katarzyna Jankiewicz; Michał Bogusiewicz; Łukasz Nowakowski; Tomasz Rechberger; Artur Rogowski; Pawel Miotla
Journal:  J Clin Med       Date:  2022-02-13       Impact factor: 4.241

Review 4.  The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.

Authors:  Sofia Tsiapakidou; Apostolos Apostolidis; Konstantinos Pantazis; Grigoris F Grimbizis; Themistoklis Mikos
Journal:  Int Urogynecol J       Date:  2021-08-07       Impact factor: 2.894

5.  Neuroepithelial control of mucosal inflammation in acute cystitis.

Authors:  Daniel S C Butler; Ines Ambite; Karoly Nagy; Caterina Cafaro; Abdulla Ahmed; Aftab Nadeem; Nina Filenko; Thi Hien Tran; Karl-Erik Andersson; Björn Wullt; Manoj Puthia; Catharina Svanborg
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

6.  A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.

Authors:  Andrzej Wróbel; Aleksandra Szopa; Anna Serefko; Ewa Poleszak
Journal:  Molecules       Date:  2020-03-18       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.